HMTX.F Stock Overview
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hemostemix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.037 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.037 |
| Beta | 0.52 |
| 1 Month Change | -16.44% |
| 3 Month Change | -45.44% |
| 1 Year Change | -70.06% |
| 3 Year Change | -83.83% |
| 5 Year Change | -96.67% |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| HMTX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 0.3% |
| 1Y | -70.1% | 2.9% | 24.2% |
Return vs Industry: HMTX.F underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: HMTX.F underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| HMTX.F volatility | |
|---|---|
| HMTX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HMTX.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HMTX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Thomas Smeenk | hemostemix.com |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Hemostemix Inc. Fundamentals Summary
| HMTX.F fundamental statistics | |
|---|---|
| Market cap | US$2.23m |
| Earnings (TTM) | -US$1.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs HMTX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HMTX.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.50m |
| Earnings | -CA$2.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -58.6% |
How did HMTX.F perform over the long term?
See historical performance and comparison